CMS

Advertisement

CMS, Medicaid Expand 2026 Coverage for Five Emerging Health Technologies

by
CMS issues major 2026 reimbursement changes impacting neuromodulation, EP ablation, wound care, sleep apnea therapy, and DKD diagnostics across the U.S.

Broader 2026 Coverage Enhances Economics Across Multiple Care Settings A sweeping set of CMS and Medicaid reimbursement decisions is reshaping 2026 access across neuromodulation, electrophysiology, advanced wound reconstruction, diagnostic testing, and regenerative biologics. From APC assignments and ASC approvals to national pricing and expanded Medicaid coverage, these updates strengthen commercial readiness for emerging technologies while … Read more

CMS Sets New Medicare 2026 Rates Across Five Innovation Categories

by
CMS Sets New Medicare 2026 Rates Across Five Innovation Categories

What the New Medicare 2026 Rates Mean for Access and Adoption The U.S. Centers for Medicare & Medicaid Services (CMS) has delivered a rare cluster of reimbursement decisions that collectively mark one of the most significant access-defining weeks of 2025. Spanning neuromodulation, molecular diagnostics, AI imaging, autoimmune disease therapy, and oncology support care, the rulings … Read more

Advertisement

CMS Finalizes SAINT Payment Stability and Major Reimbursement Gains for NeuroPace’s RNS System

by
CMS Finalizes SAINT Payment Stability and Major Reimbursement Gains for NeuroPace’s RNS System

CMS has finalized two separate 2026 rulings benefiting neuromodulation innovators: stable outpatient reimbursement for Magnus Medical’s SAINT therapy and significant payment increases for NeuroPace’s RNS System across physician and hospital settings. The updates strengthen patient access and support broader adoption of advanced brain-health technologies.

CMS Sets 2026 Medicare Premiums and Deductibles as Costs Rise and Policy Changes Take Effect

by
CMS Sets 2026 Medicare Premiums and Deductibles as Costs Rise and Policy Changes Take Effect

CMS Sets 2026 Medicare Premiums and Deductibles as Cost Pressures Mount and Regulatory Fixes Temper Increases The Centers for Medicare & Medicaid Services (CMS) has released the 2026 Medicare Parts A and B premiums, deductibles, and income-related adjustment amounts, outlining another year of steady cost increases across the program. While the updates reflect predictable inflationary … Read more

Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 10, 2025

by
Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 10, 2025

The Week’s Biggest Shifts in Payer Strategy This week’s policy and access landscape was defined by a sweeping overhaul of U.S. Medicaid drug pricing and a widening push toward value-driven reimbursement models. CMS’ newly announced GENEROUS model, paired with Most Favored Nation (MFN) pricing agreements for GLP-1s, marks a structural shift that will reshape affordability … Read more

Reimbursement Series: CMS and Europe Reimbursement Pathway Accelerates Innovation

by
CMS and Europe reimbursement pathway

In a transformative week for market access, the CMS and Europe reimbursement pathway expansion delivered several pivotal coverage and pricing decisions reshaping patient access across cardiovascular, hepatic, and oncology therapies. From CMS’s national determinations on breakthrough devices to European HTA approvals in rare disease and cancer, these developments underscore a growing transatlantic alignment between regulators … Read more

Advertisement

Medicare Expands Signatera Genome MRD Assay Coverage

by

Medicare has approved coverage for Natera’s genome-based Signatera molecular residual disease (MRD) assay under LCD L38779, extending access to beneficiaries across six cancer indications. The coverage applies to colorectal, breast, bladder, ovarian, and lung cancers, as well as pan-cancer immunotherapy monitoring, aligning with the scope of Natera’s original Signatera test. This regulatory milestone positions the … Read more